BioSpace News Archive

KAHR and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR’s lead anti-CD47 candidate, DSP107, in blood cancers.

Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021.

Jefferies Virtual Healthcare Conference on June 2, 2021 at 10:30 am ET Goldman Sachs 42 nd Annual Global Healthcare Conference on June 10, 2021 at 5:30 pm ET JMP Securities Life Science Conference on June 16, 2021 at 12:30 pm ET

Solid Biosciences Inc., a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that Joel Schneider, PhD, Chief Operating Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 3:30 p.m. ET.

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m. ET.

electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June. The conferencing details are as follows: Summer Solstice Best Ideas Conference Date: Tuesday, June 1, 2021 Time: 09:30 AM EDT Investors can register for the conference HERE .

Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the Food and Drug Administration (FDA) required toxicology studies designed to support clinical trials with PRV-002, its lead drug candidate to treat concussion (mild traumatic brain injury).

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced an agreement with former LungFit ® PH commercial licensee, Circassia Group plc.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that Harmony’s President and CEO, John Jacobs , will participate in fireside chats and host investor meetings at the following upcoming virtual conferences:

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the company will be participating virtually in the William Blair 41st Annual Growth Stock Conference.